Comparable Ablation Efficiency of 30 and 100 mCi of I-131 for Low to Intermediate Risk Thyroid Cancers Using Triple Negative Criteria |
Fatima, Nosheen
(Department of Nuclear Medicine, Dr Ziauddin Hospital)
Zaman, Maseeh uz (Department of Nuclear Medicine, Dr Ziauddin Hospital) Zaman, Areeba (Department of Nuclear Medicine, Dr Ziauddin Hospital) Zaman, Unaiza (Department of Nuclear Medicine, Dr Ziauddin Hospital) Tahseen, Rabia (Department of Nuclear Medicine, Dr Ziauddin Hospital) |
1 | Barbaro D, Verburg FA, Luster M, Reiners C, Rubello D (2010). ALARA in rhTSH stimulated post-surgical thyroid remnant ablation: what is the lowest reasonably achievable activity? Eur J Nucl Med Mol Imaging, 37, 1251-4. DOI |
2 | Cooper DS, Doherty GM, Haugen BR, et al. (2006). Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid, 16, 1-33. DOI |
3 | Fatima N, Zaman MU, Ikram M, et al (2014). Baseline stimulated thyroglobulin level as a good predictor of successful ablation after adjuvant radioiodine treatment for differentiated thyroid cancers. Asian Pac J Cancer Prev, 15, 6443-47. DOI |
4 | Fatima N, Zaman MU, Zaman A, et al (2016). Factors predicting early release of thyroid cancer patients from the isolation room after radioiodine-131 treatment. Asian Pac J Cancer Prev, 17, 125-9. DOI |
5 | Hackshaw A, Harmer C, Mallick UH, et al (2007). 131I activity for remnant ablation in patients with differentiated thyroid cancer: a systematic review. J Clin Endocrinol Metab, 92, 28-38. DOI |
6 | Haymart MR, Banerjee M, Stewart AK, et al (2011). Use of radioactive iodine for thyroid cancer. JAMA, 306, 721-8. DOI |
7 | Haugen BR, Alexander EK, Bible KC, et al (2016). 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. Thyroid, 26, 1-133 DOI |
8 | Iyer NG, Morris LG (2011). Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy. Cancer, 117, 4439-46. DOI |
9 | Maenpaa HO, Heikkonen J, VaalavirtaL, Tenhunen M, Joensuu H (2008). Low vs. high radioiodine activity to ablate the thyroid after thyroidectomy for cancer: a randomized study. PLoS One, 3, 1885. DOI |
10 | Mallick U, Harmer C, Yap B, et al (2012). Ablation with lowdose radioiodine and thyrotropin alfa in thyroid cancer. N Engl J Med, 366, 1674-85. DOI |
11 | Pacini F, Schlumberger M, Dralle H, et al (2006). European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol, 154, 787-803. DOI |
12 | Rubino C, de Vathaire F, Dottorini ME, et al (2003). Second primary malignancies in thyroid cancer patients. Br J Cancer, 89, 1638-44. DOI |
13 | Sawka AM, Thephamongkhol K, Brouwers M, et al (2004). Clinical review 170: a systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J Clin Endocrinol Metab, 89, 3668-76. DOI |
14 | Zaman MU, Fatima N, Padhy AK, et al (2013). Controversies about radioactive iodine-131 remnant ablation in low risk thyroid cancers: are we near a consensus? Asian Pac J Cancer Prev, 14, 6209-13. DOI |
15 | Sherman SI (2003). Thyroid carcinoma. Lancet, 361, 501-11. DOI |
16 | Schlumberger M, Catargi B, Borget I, et al (2012). Strategies of Radioiodine Ablation in Patients with Low-Risk Thyroid Cancer. N Engl J Med, 366, 1663-73. DOI |
![]() |